Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.85 | — | — | — | — | — | 18.19 | — | — | — | — | 21.98 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 26.43 | 9.49 | 44.40 | 40.35 | 30.63 | 35.78 | 6.36 | — | 8.21 | 15.90 | 4.76 | 3.12 | 4.34 |
| — | -73.5% | +597.9% | — | +273.3% | +125.0% | +33.6% | — | +89.0% | +86.1% | -96.4% | -98.9% | -97.0% | |
| P/B Ratio | 1.88 | 2.84 | 5.82 | 9.86 | 7.65 | 7.64 | 10.17 | 7.27 | 146.99 | 31.42 | 13.97 | — | — |
| — | -62.9% | -42.8% | +35.6% | -94.8% | -75.7% | -27.2% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 18.45 | — | — | — | — | 22.55 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 20.19 | — | — | — | — | 28.62 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Wave Life Sciences Ltd.'s operating margin was -81.8% in Q1 2026, up 245.6 pp QoQ and up 461.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -439.1% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 30.9% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.3% | 100.0% | 86.9% | 100.0% | 74.8% | 76.4% | 100.0% | 100.0% | 100.0% | 100.0% | 92.5% | 35.7% | -50.7% |
| — | +30.9% | -13.1% | 0.0% | -25.2% | -23.6% | +8.1% | +180.1% | +297.2% | +171.6% | +103.8% | +100.4% | +99.4% | |
| Operating Margin | -504.1% | -81.8% | -327.4% | -740.7% | -606.5% | -542.8% | 27.4% | 832.7% | -177.7% | -274.8% | -64.3% | 9.0% | -106.2% |
| — | +84.9% | -1294.0% | -189.0% | -241.3% | -97.5% | +142.7% | +9121.0% | -67.4% | -17.3% | +98.2% | +100.1% | +99.1% | |
| Net Margin | -478.3% | -68.2% | -308.4% | -707.8% | -580.2% | -510.9% | 34.9% | 804.8% | -167.2% | -251.7% | -55.9% | 14.7% | -95.5% |
| — | +86.7% | -982.8% | -187.9% | -247.0% | -103.0% | +162.4% | +5361.9% | -75.1% | -18.7% | +98.4% | +100.1% | +99.1% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.6% | -5.0% | -16.3% | -40.8% | -32.4% | -24.6% | 16.3% | -80.3% | -221.1% | -97.1% | -41.0% | — | — |
| — | +79.6% | -200.3% | +49.1% | +85.3% | +74.7% | +139.7% | — | — | — | — | — | — | |
| ROA | -41.3% | -4.3% | -12.1% | -21.8% | -18.7% | -14.6% | 8.2% | -21.8% | -14.8% | -12.4% | -6.8% | 3.4% | -8.5% |
| — | +70.8% | -246.8% | -0.2% | -25.9% | -18.3% | +220.2% | -745.5% | -74.7% | +6.6% | +74.3% | +117.1% | +60.9% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 281.5% YoY to 11.26x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.16 | 0.16 | 0.14 | 0.12 | 0.18 | 6.57 | 1.20 | 0.81 | — | — |
| — | -77.6% | -72.2% | -12.6% | -97.6% | -88.6% | -85.0% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | 1.01 | — | — | — | — | 5.97 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.47 | 11.26 | 6.47 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 |
| — | +281.5% | +124.0% | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | |
| Quick Ratio | 6.47 | 11.26 | 6.47 | 2.51 | 2.56 | 2.95 | 2.89 | 1.90 | 0.99 | 1.19 | 1.26 | 1.59 | 1.32 |
| — | +281.5% | +124.0% | +32.0% | +157.3% | +148.9% | +128.7% | +19.8% | -24.5% | -28.4% | -8.4% | -22.5% | -47.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Total return calculator · dividends reinvested
Calculate ReturnsDollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Compare NowQuick answers to the most common questions about buying WVE stock.
Wave Life Sciences Ltd.'s current P/E is -4.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Wave Life Sciences Ltd.'s current operating margin is -504.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Wave Life Sciences Ltd.'s business trajectory between earnings reports.